Remdesivir News and Research

RSS

Remdesivir inhibits SARS-CoV-2 replication by preventing RdRp-mediated RNA translocation

A new study describes the in vitro mechanism by which remdesivir kinetically inhibits the replication of the virus that causes COVID-19, SARS-CoV-2.

18 Dec 2020

Hepatitis C virus drugs synergize with remdesivir against SARS-CoV-2 in vitro

SARS-CoV-2 has infected over 71.5 million people and claimed over 1.6 million lives globally since December 2019.

17 Dec 2020

Research reveals two phases of infection in patients with severe COVID-19 pneumonia

What does SARS-CoV-2, the virus that causes COVID-19, do once it enters a person's airways, and how does infection in lung cells affect patients' immune responses?

16 Dec 2020

Azithromycin trial fails to provide evidence of benefit in COVID-19

Early on in the COVID-19 pandemic, azithromycin was regarded as being a potentially highly effective drug against the virus that causes it, SARS-CoV-2.

16 Dec 2020

Copper gluconate supplementation could reduce SARS-CoV-2 infection in vitro

The second wave of COVID-19 has affected many countries, costing thousands of lives and dealing further heavy blows to already reeling economies.

16 Dec 2020

First enzyme-driven biocatalytic production of nucleic acid building blocks

Researchers from TU Graz and acib succeed in the first enzyme-driven biocatalytic synthesis of nucleic acid building blocks. This facilitates the development of antiviral agents and RNA-based therapeutics.

15 Dec 2020

Remdesivir likely to be highly effective treatment for COVID-19

The drug remdesivir is likely to be a highly effective antiviral against SARS-CoV-2, according to a new study by a team of UK scientists.

14 Dec 2020

Emergence of resistant SARS-CoV-2 variant in immunocompromised patient following therapeutic antibody use

The focus is increasingly moving towards vaccine roll-out as the world faces the real possibility of the second year of social and economic restrictions.

14 Dec 2020

Combination of baricitinib and remdesivir could benefit some COVID-19 patients

The combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19, according to clinical trial results published in the New England Journal of Medicine.

11 Dec 2020

Favipiravir does not attenuate the progression of COVID-19

Scientists have conducted an observational study to evaluate the efficacy of an anti-influenza medicine favipiravir in treating hospitalized COVID-19 patients.

11 Dec 2020

Researchers use AI platform to identify best combination of available therapies against COVID-19.

A team of researchers from the National University of Singapore (NUS) has utilized a ground-breaking artificial intelligence (AI) platform to derive an optimal combination of available therapies against SARS-CoV-2, the cause of COVID-19.

11 Dec 2020

Using AI to find optimal combination of available therapies against SARS-CoV-2

A team of researchers from the National University of Singapore has utilized a ground-breaking artificial intelligence (AI) platform to derive an optimal combination of available therapies against SARS-CoV-2, the cause of COVID-19.

10 Dec 2020

A battle-weary Seattle hospital fights the latest COVID surge

As hospitals across the country weather a surge of COVID-19 patients, in Seattle — an early epicenter of the outbreak — nurses, respiratory therapists and physicians are staring down a startling resurgence of the coronavirus that’s expected to test even one of the best-prepared hospitals on the pandemic’s front lines.

10 Dec 2020

Amilorides reduce SARS-CoV-2 viral replication in vitro

A new U.S. study published on the bioRxiv preprint server reports the use of an amiloride-based scaffold that targets a viral RNA structure known to be essential in viral replication in the 5’-untranslated region (UTR) of the virus. The researchers say this heralds the application of these molecules as chemical probes to explore viral biology and produce specific antivirals targeting RNA regions of the coronavirus genome.

8 Dec 2020

Remdesivir News and Research

Remdesivir inhibits SARS-CoV-2 replication by preventing RdRp-mediated RNA translocation

Hepatitis C virus drugs synergize with remdesivir against SARS-CoV-2 in vitro

Research reveals two phases of infection in patients with severe COVID-19 pneumonia

Azithromycin trial fails to provide evidence of benefit in COVID-19

Copper gluconate supplementation could reduce SARS-CoV-2 infection in vitro

First enzyme-driven biocatalytic production of nucleic acid building blocks

Remdesivir likely to be highly effective treatment for COVID-19

Emergence of resistant SARS-CoV-2 variant in immunocompromised patient following therapeutic antibody use

Combination of baricitinib and remdesivir could benefit some COVID-19 patients

Favipiravir does not attenuate the progression of COVID-19

Researchers use AI platform to identify best combination of available therapies against COVID-19.

Using AI to find optimal combination of available therapies against SARS-CoV-2

A battle-weary Seattle hospital fights the latest COVID surge

Amilorides reduce SARS-CoV-2 viral replication in vitro

Molecular simulations reveal that remdesivir targets two SARS-CoV-2 enzymes

Can melatonin help prevent severe COVID-19?

Study: Infants diagnosed with COVID-19 experienced reversible myocardial injury, heart failure

Research suggests plant flavonols could serve as effective antivirals for SARS-CoV-2

Potential SARS-CoV-2 antiviral: Ionophore X-206 found to inhibit viral replication in cell cultures

Nucleic acid-hydrolyzing scFv 3D8 exhibits potent antiviral effects on SARS-CoV-2

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News